Trial Profile
Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms OXIDISE
- Sponsors GWT-TUD GmbH
- 24 May 2023 This trial has been discontinued, according to European Clinical Trials Database record.
- 02 Dec 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 21 Oct 2021 Planned End Date changed from 1 Jun 2023 to 1 Aug 2023.